Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of CS2009 in combination therapies for advanced solid tumors

Next Previous
Trial Profile

A phase II trial of CS2009 in combination therapies for advanced solid tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS 2009 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 20 Jul 2026 According to a CStone Pharmaceuticals media release, company announced that one of its core assets CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has been accepted for two Rapid Oral presentations at the European Society for Medical Oncology (ESMO) Congress 2026.
  • 17 Feb 2026 According to a CStone Pharmaceuticals media release, The Phase II study is currently actively enrolling patients in Australia.
  • 17 Feb 2026 According to a CStone Pharmaceuticals media release, company announced that the Investigational New Drug (IND) application for the Phase II clinical trials of CS2009 combination therapies for advanced solid tumors has been approved by the China National Medical Products Administration (NMPA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top